全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis

A Novel Unsupervised Method to Identify Genes Important in the Anti-viral Response: Application to Interferon/Ribavirin in Hepatitis C Patients

Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C

Three Patients with Viral Breakthrough During Pegylated Interferon Alpha-2b and Ribavirin Therapy: A Case Series

Ribavirin in acute viral hepatitis.

Effect of hepatic iron concentration and viral factors in chronic hepatitis C-infected patients with thalassemia major, treated with interferon and ribavirin

Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin

Effect of hepatic iron concentration and viral factors in chronic hepatitis C-infected patients with thalassemia major, treated with interferon and ribavirin

A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon

更多...

Effectiveness of alpha interferon (+ ribavirin) in the treatment of chronic viral hepatitis C genotypes 2 and 3 in a brazilian sample

DOI: 10.1590/S0004-28032012000200010

Keywords: hepatitis c, chronic, interferon alpha, ribavirin, adverse drug reaction reporting systems.

Full-Text   Cite this paper   Add to My Lib

Abstract:

context: pharmacovigilance studies aim to detect, assess, understand and prevent risks of adverse effects of medications or any other possible drug related problem. alpha interferon is being produced by bio-manguinhos/fiocruz, rio de janeiro, rj, brazil and used in the treatment of chronic hepatitis c at brazilian national health system. objective: to study the safety profile and effectiveness of alpha interferon in a sample of brazilian patients with chronic hepatitis c genotypes 2 and 3, in porto alegre, rs, brazil. method: we followed a cohort of chronic hepatitis c genotypes 2 and 3 patients treated with alpha interferon plus ribavirin in a specialized outpatient clinic in southern brazil. adverse events were collected and classified according to severity in monthly structured interviews. to measure effectiveness, hepatitis c viral load was evaluated before, at the end and 24 weeks after the treatment. results: we followed 141 patients during the study period, of which 52.5% were female with mean age of 52 years. the most frequent adverse events were fatigue (84%), headache (79%) and myalgia (75%). there were 13 treatment interruptions due to adverse events, 9 of those considered serious adverse events. virological response at end of treatment was 54.6% and after 24 weeks 39.7%, considering all patients who started treatment. conclusion: the product produced by bio-manguinhos has similar efficacy and adverse event and sustained virological response profiles comparable to those found in the literature. this is the first study of pharmacovigilance performed with the brazilian product. these data will be useful for planning and management of this disease in brazil.

Full-Text

comments powered by Disqus